Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Mouse (Murine) Complement Factor I Antikörper:
anti-Human Complement Factor I Antikörper:
anti-Rat (Rattus) Complement Factor I Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Monoclonal Complement Factor I Primary Antibody für FACS, IHC (p) - ABIN315441
Crook, Hunt: Enrichment of early fetal-liver hemopoietic stem cells of the rat using monoclonal antibodies against the transferrin receptor, Thy-1, and MRC-OX82. in Developmental immunology 1996
Human Monoclonal Complement Factor I Primary Antibody für IP, RIA - ABIN2473072
Hsiung, Barclay, Brandon, Sim, Porter: Purification of human C3b inactivator by monoclonal-antibody affinity chromatography. in The Biochemical journal 1982
Show all 2 Pubmed References
Human Monoclonal Complement Factor I Primary Antibody für Func, IHC (fro) - ABIN2473071
Ernberg: Studies on Epstein-Barr virus-associated antigens. in Annals of the New York Academy of Sciences 1975
Show all 2 Pubmed References
Factor I-mediated generation of activated C3 fragments in the circulation is a critical determinant for the development of MPGN2 associated with factor H (zeige CFH Antikörper) deficiency.
This finding although rare does suggest that screening for chromosomal rearrangements affecting CFI should be undertaken in all aHUS patients particularly if the factor I level is unexplainably low.
Factor I binds C3b-Factor H (zeige CFH Antikörper) between Factor H (zeige CFH Antikörper) domains 2 and 3 and a reoriented C3b C-terminal domain and docks onto the first scissile bond, while stabilizing its catalytic domain for proteolytic activity.
Taken together, our data argue that multiple rare and ultra-rare alleles in CFI contribute to AMD (zeige AMD1 Antikörper) pathogenesis; they improve the precision of the assessment of the contribution of CFI to AMD (zeige AMD1 Antikörper)
Case Report: thrombotic microangiopathy with mutations in complement factor I and thrombomodulin (zeige THBD Antikörper).
Our results indicate that CFI polymorphisms are not significantly associated with VKH syndrome.
Patients with advanced atrophic AMD (zeige AMD1 Antikörper) carried these rare variants more frequently than patients with neovascular AMD (zeige AMD1 Antikörper) (11 of 93 [11.8%] vs 40 of 835 [4.8%]; P = .04).
Low FI levels are strongly associated with rare CFI variants and age-related macular degeneration.
A missense variant (p.V412M) in CFI was discovered in two Tunisian Jewish families with early-onset age-related macular degeneration.
Regulatory components of the alternative complement pathway in endothelial cell cytoplasm, factor H (zeige CFH Antikörper) and factor I, are not packaged in Weibel-Palade bodies.
In this study, the odds of AMD (zeige AMD1 Antikörper) were highest in those with deficient vitamin D status and 2 risk alleles for the CFH (zeige CFH Antikörper) and CFI genotypes, suggesting a synergistic effect between vitamin D status and complement cascade protein function.
This gene encodes a serine proteinase that is essential for regulating the complement cascade. The encoded preproprotein is cleaved to produce both heavy and light chains, which are linked by disulfide bonds to form a heterodimeric glycoprotein. This heterodimer can cleave and inactivate the complement components C4b and C3b, and it prevents the assembly of the C3 and C5 convertase enzymes. Defects in this gene cause complement factor I deficiency, an autosomal recessive disease associated with a susceptibility to pyogenic infections. Mutations in this gene have been associated with a predisposition to atypical hemolytic uraemic syndrome, a disease characterized by acute renal failure, microangiopathic hemolytic anemia and thrombocytopenia. Primary glomerulonephritis with immmune deposits is another condition associated with mutation of this gene.
complement factor I
, I factor (complement)
, complement factor 1
, C3B/C4B inactivator
, Konglutinogen-activating factor
, complement component I
, complement control protein factor I
, complement factor I heavy chain
, light chain of factor I
, complement component 1